Skip to main content
. 2024 Mar 11;13(3):1508–1518. doi: 10.21037/tcr-23-1333

Figure 3.

Figure 3

Patients of No. 15 (A,B: before treatment; C,D: after treatment) and No. 19 (E,F: before treatment; G,H: after treatment) with locally advanced, unresectable hepatocellular carcinoma received 3.0 Gy*15 f intensity-modulated radiotherapy plus 4 cycles of bevacizumab plus 5 cycles of pembrolizumab, and both achieved partial response, and finally underwent curative surgical resection of residual tumor. The red circles indicated the boundaries of tumor nodules.